Commentary
Video
Dr Kamdar on Results From a Subgroup Analysis of Liso-Cel in MCL
Author(s):
Manali Kamdar, MD, discusses the results of the phase 3 TRANSFORM trial in relapsed/refractory large B-cell lymphoma (LBCL) that were presented during the 2021 ASH Annual Meeting & Exposition.
Manali Kamdar, MD, associate professor, medicine, hematology-oncology; clinical director, Lymphoma Services, University of Colorado Anschutz School of Medicine, discusses responses achieved with lisocabtagene maraleucel (liso-cel; Breyanzi) according to prior lines of therapy and BTK inhibitor exposure in the mantle cell lymphoma (MCL) cohort of the phase 3 TRANSCEND NHL 001 trial (NCT02631044), as presented at the 2024 EHA Hybrid Congress.
Related Videos
Related Content
%20(2)%201-Recovered-Recovered-Recovered-Recovered-Recovered.jpg?fit=crop&auto=format)
